Contents
Key findings
- 1AOD-9604 is a small fragment of human growth hormone (the 176-191 piece) designed to trigger fat breakdown without growth hormone's other effects.
- 2It reliably increased fat burning and weight loss in animal studies.
- 3In humans the story is much weaker - a small early trial hinted at modest weight loss, but the larger, better-designed trial failed to beat placebo.
- 4The full results of that pivotal human trial were never published in a peer-reviewed journal, and the obesity program was discontinued around 2007.
- 5It is not FDA-approved; the "fat-loss peptide" sold online rests mostly on mouse data and marketing, not proven human results.
Evidence level
AOD-9604 has good animal data and a small early human hint of modest fat loss, but its larger, more rigorous human trial did not beat placebo - and, tellingly, those full results were never published. The human evidence is weak and contradictory.
Regulatory status
AOD-9604 is not FDA-approved for any use. It was developed as an obesity drug, failed to show clear benefit in its pivotal trial, and the program was wound down in the mid-2000s. It is now sold as an unapproved research peptide.
AOD-9604 is marketed as a clever fat-loss peptide: a tiny piece of growth hormone that burns fat without the downsides of growth hormone itself. It is a genuinely interesting idea, and it worked in animals. The problem is what happened when it was tested properly in people - which is a story the sellers rarely tell.
What AOD-9604 is
Growth hormone has many jobs. One of them is helping break down fat. Researchers took the specific fragment of the growth hormone molecule thought to do the fat-burning part - the 176-191 piece - and made it on its own. That fragment is AOD-9604.
The hope was elegant: get the fat-breakdown effect without growth hormone's other actions, like raising blood sugar or growing tissue[1].
The animal data (the strong part)
In studies of obese mice, AOD-9604 did what it was designed to do: it increased fat oxidation (fat burning) and reduced body weight[1]. This is why the peptide got attention in the first place, and why the mechanism is often described so confidently online.
But mouse results are a starting point, not a conclusion. Plenty of compounds work beautifully in mice and then do nothing in people. To know if AOD-9604 works for humans, you have to look at the human trials - and this is where it falls apart.
The human data (the weak part)
Here is the honest sequence:
- A small early human trial hinted at modest weight loss over about 12 weeks. Encouraging, but small and short - proof of concept, not proof of benefit.
- The developer, an Australian company, then ran a larger, more rigorous trial in obese adults - the kind of study that actually settles the question.
- That pivotal trial did not beat placebo on its main efficacy measure, and the obesity program was wound down around 2007.
And here is the detail that should make anyone pause: the full results of that failed pivotal trial were never published in a peer-reviewed journal. When a promising drug's biggest trial fails and the data quietly never appears, that absence is information. It usually means the answer was disappointing.
What people say versus what was shown
The marketing leans almost entirely on the mouse data and the mechanism ("it's the fat-burning part of growth hormone!"). Both are real. What the marketing skips is that the one human test designed to prove it works didn't. So the confident "AOD-9604 burns fat" claim is, for humans, closer to hope than to evidence.
On safety, the short human trials that were run reported it as generally well tolerated - but "well tolerated in a drug that also doesn't clearly work" is a thin selling point, and it is not FDA-approved for anything.
The bottom line
AOD-9604 is a good example of why animal data and mechanism are not enough. The idea is smart, the mouse results are real, and the human results are weak, conflicting, and - at the decisive moment - unpublished. Until there is solid published human evidence, "fat-loss peptide" is a description of the marketing, not the proof.
Where to go next
- Peptides for weight loss: what the evidence supports
- How to read peptide research
- Retatrutide: the triple-hormone weight-loss drug still in trials
- FDA-approved, off-label, investigational and unapproved peptides
Frequently asked questions
- Does AOD-9604 actually work for fat loss?
- In mice, yes - it increased fat burning. In humans the evidence is weak and conflicting: a small early trial suggested modest weight loss, but the larger, more rigorous trial failed to beat placebo. So there is no solid human proof that it works.
- Is AOD-9604 FDA-approved?
- No. It was developed as an obesity drug but never gained approval after its pivotal trial failed to show clear benefit. It is now sold as an unapproved research peptide.
- Why did AOD-9604 never become a weight-loss drug?
- Its larger human trial did not separate from placebo on the main efficacy measure, and the obesity program was wound down in the mid-2000s. Notably, those full results were never published in a peer-reviewed journal.
- Is AOD-9604 the same as growth hormone?
- No. It is a small fragment of the growth hormone molecule (the 176-191 portion), chosen to try to trigger fat breakdown without growth hormone's effects on blood sugar or tissue growth.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment International Journal of Obesity (PubMed 11673763), 2001.
Preclinical
Result: In obese mice, chronic treatment with growth hormone or its modified C-terminal fragment (AOD-9604) increased fat oxidation and reduced body weight, supporting the mechanistic idea behind AOD-9604 - but in animals, not humans.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
